Editas Medicine, Inc. · Transaction Apr 10, 2023 · Filed May 19, 2023 · $1,001 to $15,000
NASDAQ NMS - GLOBAL MARKET · EDIT
+3.17% · +$0.0800 · Vol 2.2M
After hours · updated 17:10:41 ET
Editas Medicine Inc
Biotechnology
$2.60
Follow $EDIT
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $EDIT by emailVeridion Score
BETAHIGH CONF · 6 of 6 factors measuredFri Oct 2 · session closed · Markets closed · resumes Mon 9:30 ET · EDIT
MethodologyEDIT
Editas Medicine Inc
Fri Oct 2 · session closed · Markets closed · resumes Mon 9:30 ET
Middle range
Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
52/ 100
Veridion Score
Middle range · HIGH confidence · 6 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: HIGH · 6 of 6 factors measured · Fri Oct 2 · session closed · Markets closed · resumes Mon 9:30 ET
Veridion Score History · 90D
Loading score history
AI Analysis
SovereignWhy is EDIT moving today?
Sovereign unlock connects news, insider activity, analyst moves, and live price action.
About Editas Medicine Inc
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)Listed since
2016
Employees
87
Country
US
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
Key statistics
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Open
$2.57
Day high
$2.63
Day low
$2.51
Previous close
$2.52
52W high
$4.15
-37.35% from high
52W low
$1.67
38% of range
Market cap
$387M
EPS
$-1.3200
Beta
1.64
Shares out
153.6M
Volume
2.2M
0.75× rel vol
Avg volume
2.9M
VWAP
$2.58
Price history computed in-house
1W
+0.78%
1M
-15.58%
3M
-28.77%
1Y
-33.16%
YTD
+26.83%
SMA 50 $2.83 · below
SMA 200 $2.64 · below
52W position 38%
EDIT overview
Related filings and maps
Public disclosures
Congress activity in EDIT
Official filing ↗
Editas Medicine, Inc. · Transaction Apr 14, 2021 · Filed May 1, 2021 · $1,001 to $15,000
Editas Medicine, Inc. · Transaction Mar 2, 2021 · Filed Apr 1, 2021 · $1,001 to $15,000
Editas Medicine, Inc. · Transaction Nov 17, 2020 · Filed Dec 1, 2020 · $1,001 to $15,000
Editas Medicine, Inc. · Transaction May 1, 2020 · Filed May 31, 2020 · $1,001 to $15,000
Federal contracts
EDIT contract awards, year to date.
Public federal awards linked to this ticker.
Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for EDIT in this window.
Lobbying spend
EDIT lobbying filings, year to date.
Registered lobbying filings matched to Editas Medicine Inc.
Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for EDIT in this window.
Analyst ratings
Sovereign unlock shows live analyst consensus for EDIT.
Options
Options data is temporarily unavailable. Changing your plan will not restore the upstream feed.